{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:14Z","timestamp":1792587734407,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/15\/2023-5901"],"award-info":[{"award-number":["EMDR\/SG\/15\/2023-5901"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04064-z","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:39:15Z","timestamp":1759937955000},"page":"1085-1100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Epidrugs in cancer: mechanisms, applications, and future direction"],"prefix":"10.1007","volume":"28","author":[{"given":"Roshni","family":"Bibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Varshetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakshit Kamal","family":"Lahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahnavi","family":"Namburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardeen Ahmed","family":"Laskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-6688","authenticated-orcid":false,"given":"Koustav","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"4064_CR1","doi-asserted-by":"publisher","unstructured":"The global challenge of cancer. Nat Cancer. 2020;1:1\u20132. https:\/\/doi.org\/10.1038\/s43018-019-0023-9.","DOI":"10.1038\/s43018-019-0023-9"},{"issue":"2","key":"4064_CR2","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.1002\/cnr2.1764","volume":"6","author":"A Pulumati","year":"2023","unstructured":"Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RVL. Technological advancements in cancer diagnostics: improvements and limitations. Cancer Rep (Hoboken, NJ). 2023;6(2):e1764. https:\/\/doi.org\/10.1002\/cnr2.1764.","journal-title":"Cancer Rep (Hoboken, NJ)"},{"key":"4064_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41591-022-01746-x","volume":"28","author":"RC Fitzgerald","year":"2022","unstructured":"Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N. The future of early cancer detection. Nat Med. 2022;28:666\u201377. https:\/\/doi.org\/10.1038\/s41591-022-01746-x.","journal-title":"Nat Med"},{"key":"4064_CR4","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50:9663\u201376. https:\/\/doi.org\/10.1007\/s11033-023-08809-3.","journal-title":"Mol Biol Rep"},{"key":"4064_CR5","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370. https:\/\/doi.org\/10.1177\/20503121211034366.","journal-title":"SAGE Open Med"},{"issue":"8","key":"4064_CR6","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.cell.2023.02.015","volume":"186","author":"D Wang","year":"2023","unstructured":"Wang D, Liu B, Zhang Z. Accelerating the understanding of cancer biology through the lens of genomics. Cell. 2023;186(8):1755\u201371. https:\/\/doi.org\/10.1016\/j.cell.2023.02.015.","journal-title":"Cell"},{"issue":"1","key":"4064_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","volume":"21","author":"F Kroschinsky","year":"2017","unstructured":"Kroschinsky F, St\u00f6lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89. https:\/\/doi.org\/10.1186\/s13054-017-1678-1.","journal-title":"Crit Care"},{"issue":"1","key":"4064_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/life12010048","volume":"12","author":"D Basak","year":"2021","unstructured":"Basak D, Arrighi S, Darwiche Y, Deb S. Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life. 2021;12(1):48. https:\/\/doi.org\/10.3390\/life12010048.","journal-title":"Life"},{"issue":"4","key":"4064_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1057\/biosoc.2014.22","volume":"9","author":"M Meloni","year":"2014","unstructured":"Meloni M, Testa G. Scrutinizing the epigenetics revolution. BioSocieties. 2014;9(4):431\u201356. https:\/\/doi.org\/10.1057\/biosoc.2014.22.","journal-title":"BioSocieties"},{"issue":"3","key":"4064_CR10","doi-asserted-by":"publisher","first-page":"A160","DOI":"10.1289\/ehp.114-a160","volume":"114","author":"B Weinhold","year":"2006","unstructured":"Weinhold B. Epigenetics: the science of change. Environ Health Perspect. 2006;114(3):A160\u20137. https:\/\/doi.org\/10.1289\/ehp.114-a160.","journal-title":"Environ Health Perspect"},{"issue":"1","key":"4064_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ydbio.2016.06.005","volume":"416","author":"U Deichmann","year":"2016","unstructured":"Deichmann U. Epigenetics: the origins and evolution of a fashionable topic. Dev Biol. 2016;416(1):249\u201354. https:\/\/doi.org\/10.1016\/j.ydbio.2016.06.005.","journal-title":"Dev Biol"},{"key":"4064_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-94-007-4525-4_13","volume":"61","author":"JL Miller","year":"2013","unstructured":"Miller JL, Grant PA. The role of DNA methylation and histone modifications in transcriptional regulation in humans. Subcell Biochem. 2013;61:289\u2013317. https:\/\/doi.org\/10.1007\/978-94-007-4525-4_13.","journal-title":"Subcell Biochem"},{"key":"4064_CR13","unstructured":"Alberts B, Johnson A, Lewis J, Raff M, Roberts K, and Walter P. Control of gene expression. Molecular biology of the cell - NCBI Bookshelf. 2002. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK21057\/"},{"key":"4064_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-43624-1_7","volume":"945","author":"R Lakshminarasimhan","year":"2016","unstructured":"Lakshminarasimhan R, Liang G. The role of DNA methylation in cancer. Adv Exp Med Biol. 2016;945:151\u201372. https:\/\/doi.org\/10.1007\/978-3-319-43624-1_7.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"4064_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/1099800412444785","volume":"15","author":"KE Stephens","year":"2013","unstructured":"Stephens KE, Miaskowski CA, Levine JD, Pullinger CR, Aouizerat BE. Epigenetic regulation and measurement of epigenetic changes. Biol Res Nurs. 2013;15(4):373\u201381. https:\/\/doi.org\/10.1177\/1099800412444785.","journal-title":"Biol Res Nurs"},{"issue":"1","key":"4064_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.34172\/mejdd.2025.404","volume":"17","author":"Z Taheri","year":"2025","unstructured":"Taheri Z, Zaki-Dizaji M. Epigenetically regulating non-coding RNAs in colorectal cancer: promises and potentials. Middle East J Dig Dis. 2025;17(1):40\u201353. https:\/\/doi.org\/10.34172\/mejdd.2025.404.","journal-title":"Middle East J Dig Dis"},{"key":"4064_CR17","doi-asserted-by":"publisher","first-page":"154688","DOI":"10.1016\/j.prp.2023.154688","volume":"248","author":"MR Farani","year":"2023","unstructured":"Farani MR, Sarlak M, Gholami A, Azaraian M, Binabaj MM, Kakavandi S, et al. Epigenetic drugs as new emerging therapeutics: what is the scale\u2019s orientation of application and challenges? Pathol Res Pract. 2023;248:154688. https:\/\/doi.org\/10.1016\/j.prp.2023.154688.","journal-title":"Pathol Res Pract"},{"key":"4064_CR18","doi-asserted-by":"publisher","first-page":"605386","DOI":"10.3389\/fonc.2020.605386","volume":"10","author":"M Montalvo-Casimiro","year":"2020","unstructured":"Montalvo-Casimiro M, Gonz\u00e1lez-Barrios R, Meraz-Rodriguez MA, Ju\u00e1rez-Gonz\u00e1lez VT, Arriaga-Canon C, Herrera LA. Epidrug repurposing: discovering new faces of old acquaintances in cancer therapy. Front Oncol. 2020;10:605386. https:\/\/doi.org\/10.3389\/fonc.2020.605386.","journal-title":"Front Oncol"},{"issue":"4","key":"4064_CR19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"key":"4064_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Sig Transduct Target Ther. 2024;9:332. https:\/\/doi.org\/10.1038\/s41392-024-02039-0.","journal-title":"Sig Transduct Target Ther"},{"key":"4064_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13148-019-0776-0","volume":"11","author":"A Ganesan","year":"2019","unstructured":"Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M, et al. The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenet. 2019;11:174. https:\/\/doi.org\/10.1186\/s13148-019-0776-0.","journal-title":"Clin Epigenet"},{"issue":"12","key":"4064_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/biom14121605","volume":"14","author":"MA Theodoropoulou","year":"2024","unstructured":"Theodoropoulou MA, Mantzourani C, Kokotos G. Histone deacetylase (HDAC) inhibitors as a novel therapeutic option against fibrotic and inflammatory diseases. Biomolecules. 2024;14(12):1605. https:\/\/doi.org\/10.3390\/biom14121605.","journal-title":"Biomolecules"},{"issue":"2","key":"4064_CR23","first-page":"166","volume":"3","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3(2):166\u201379.","journal-title":"Am J Transl Res"},{"key":"4064_CR24","doi-asserted-by":"publisher","first-page":"119504","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504. https:\/\/doi.org\/10.1016\/j.lfs.2021.119504.","journal-title":"Life Sci"},{"issue":"19","key":"4064_CR25","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","volume":"6","author":"MM Coud\u00e9","year":"2015","unstructured":"Coud\u00e9 MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015;6(19):17698\u2013712. https:\/\/doi.org\/10.18632\/oncotarget.4131.","journal-title":"Oncotarget"},{"issue":"7","key":"4064_CR26","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1078-0432.ccr-14-1561","volume":"21","author":"M Boi","year":"2015","unstructured":"Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21(7):1628\u201338. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-1561.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4064_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1021\/acschembio.2c00062","volume":"17","author":"MY Wang","year":"2022","unstructured":"Wang MY, Liow P, Guzman MIT, Qi J. Exploring methods of targeting histone methyltransferases and their applications in cancer therapeutics. ACS Chem Biol. 2022;17(4):744\u201355. https:\/\/doi.org\/10.1021\/acschembio.2c00062.","journal-title":"ACS Chem Biol"},{"issue":"5","key":"4064_CR28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/febs.15750","volume":"289","author":"S Feng","year":"2022","unstructured":"Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 2022;289(5):1214\u201339. https:\/\/doi.org\/10.1111\/febs.15750.","journal-title":"FEBS J"},{"key":"4064_CR29","doi-asserted-by":"publisher","first-page":"2568635","DOI":"10.1155\/2016\/2568635","volume":"2016","author":"EG Tora\u00f1o","year":"2016","unstructured":"Tora\u00f1o EG, Garc\u00eda MG, Fern\u00e1ndez-Morera JL, Ni\u00f1o-Garc\u00eda P, Fern\u00e1ndez AF. The impact of external factors on the epigenome. In utero and over lifetime. BioMed Res Int. 2016;2016:2568635. https:\/\/doi.org\/10.1155\/2016\/2568635.","journal-title":"BioMed Res Int"},{"issue":"3","key":"4064_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/biom12030367","volume":"12","author":"A Bouyahya","year":"2022","unstructured":"Bouyahya A, Mechchate H, Oumeslakht L, Zeouk I, Aboulaghras S, Balahbib A, et al. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions. Biomolecules. 2022;12(3):367\u2013367. https:\/\/doi.org\/10.3390\/biom12030367.","journal-title":"Biomolecules"},{"issue":"11","key":"4064_CR31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/genes11111336","volume":"11","author":"J Loaeza-Loaeza","year":"2020","unstructured":"Loaeza-Loaeza J, Beltran AS, Hern\u00e1ndez-Sotelo D. DNMTs and impact of CpG content, transcription factors, consensus motifs, lncRNAs, and histone marks on DNA methylation. Genes. 2020;11(11):1336. https:\/\/doi.org\/10.3390\/genes11111336.","journal-title":"Genes"},{"key":"4064_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-9967-2_1","volume":"754","author":"B Jin","year":"2013","unstructured":"Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3\u201329. https:\/\/doi.org\/10.1007\/978-1-4419-9967-2_1.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"4064_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","volume":"18","author":"EJ Derissen","year":"2013","unstructured":"Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist. 2013;18(5):619\u201324. https:\/\/doi.org\/10.1634\/theoncologist.2012-0465.","journal-title":"Oncologist"},{"issue":"Supplement 1","key":"4064_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141539","volume":"136","author":"M Saiz-Rodr\u00edguez","year":"2020","unstructured":"Saiz-Rodr\u00edguez M, Cuevas B, Mart\u00ednez-Cuadr\u00f3n D, Campuzano V, Cuevas MV, Hermida G, et al. Comparison of azacitidine and decitabine for the treatment of acute myeloid leukemia: a systematic review and meta-analysis. Blood. 2020;136(Supplement 1):35\u20136. https:\/\/doi.org\/10.1182\/blood-2020-141539.","journal-title":"Blood"},{"key":"4064_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2023.01.001","author":"S Acharjee","year":"2023","unstructured":"Acharjee S, Chauhan S, Pal R, Tomar RS. Mechanisms of DNA methylation and histone modifications. Prog Mol Biol Transl Sci. 2023. https:\/\/doi.org\/10.1016\/bs.pmbts.2023.01.001.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"4","key":"4064_CR36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","volume":"35","author":"X Gu","year":"2020","unstructured":"Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, et al. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia. 2020;35(4):1023\u201336. https:\/\/doi.org\/10.1038\/s41375-020-1003-x.","journal-title":"Leukemia"},{"key":"4064_CR37","doi-asserted-by":"publisher","first-page":"1495221","DOI":"10.3389\/fimmu.2024.1495221","volume":"15","author":"X Duan","year":"2024","unstructured":"Duan X, Xing Z, Qiao L, Qin S, Zhao X, Gong Y, et al. The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. Front Immunol. 2024;15:1495221. https:\/\/doi.org\/10.3389\/fimmu.2024.1495221.","journal-title":"Front Immunol"},{"key":"4064_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/abr.abr_142_19","volume":"8","author":"M Sanaei","year":"2019","unstructured":"Sanaei M, Kavoosi F. Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers. Adv Biomed Res. 2019;8:63. https:\/\/doi.org\/10.4103\/abr.abr_142_19.","journal-title":"Adv Biomed Res"},{"issue":"9","key":"4064_CR39","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1358\/dot.2007.43.9.1112980","volume":"43","author":"M Duvic","year":"2007","unstructured":"Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc). 2007;43(9):585\u201399. https:\/\/doi.org\/10.1358\/dot.2007.43.9.1112980.","journal-title":"Drugs Today (Barc)"},{"issue":"12","key":"4064_CR40","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1111\/bcp.14889","volume":"87","author":"AD Bondarev","year":"2021","unstructured":"Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schi\u00f6th HB. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol. 2021;87(12):4577\u201397. https:\/\/doi.org\/10.1111\/bcp.14889.","journal-title":"Br J Clin Pharmacol"},{"key":"4064_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh3351","author":"W Dai","year":"2022","unstructured":"Dai W, Wu F, McMyn N, Song B, Walker-Sperling VE, Varriale J, et al. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir. Sci Transl Med. 2022. https:\/\/doi.org\/10.1126\/scitranslmed.abh3351.","journal-title":"Sci Transl Med"},{"key":"4064_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01904-w","author":"Y Luan","year":"2024","unstructured":"Luan Y, Li X, Luan Y, Luo J, Dong Q, Ye S, et al. Therapeutic challenges in peripheral T-cell lymphoma. Mol Cancer. 2024. https:\/\/doi.org\/10.1186\/s12943-023-01904-w.","journal-title":"Mol Cancer"},{"issue":"2","key":"4064_CR43","doi-asserted-by":"publisher","first-page":"e001696","DOI":"10.1136\/jitc-2020-001696","volume":"9","author":"Y Que","year":"2021","unstructured":"Que Y, Zhang X-L, Liu Z-X, Zhao J-J, Pan Q-Z, Wen X-Z, et al. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. J Immunother Cancer. 2021;9(2):e001696. https:\/\/doi.org\/10.1136\/jitc-2020-001696.","journal-title":"J Immunother Cancer"},{"key":"4064_CR44","doi-asserted-by":"publisher","first-page":"818891","DOI":"10.3389\/fphar.2022.818891","volume":"13","author":"HA Ali","year":"2022","unstructured":"Ali HA, Li Y, Bilal AHM, Qin T, Yuan Z, Zhao W. A comprehensive review of BET protein biochemistry, physiology, and pathological roles. Front Pharmacol. 2022;13:818891. https:\/\/doi.org\/10.3389\/fphar.2022.818891.","journal-title":"Front Pharmacol"},{"key":"4064_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","volume":"6","author":"N Wang","year":"2021","unstructured":"Wang N, Wu R, Tang D, et al. The BET family in immunity and disease. Sig Transduct Target Ther. 2021;6:23. https:\/\/doi.org\/10.1038\/s41392-020-00384-4.","journal-title":"Sig Transduct Target Ther"},{"key":"4064_CR46","doi-asserted-by":"publisher","first-page":"728777","DOI":"10.3389\/fmolb.2021.728777","volume":"8","author":"KL Cheung","year":"2021","unstructured":"Cheung KL, Kim C, Zhou MM. The functions of BET proteins in gene transcription of biology and diseases. Front Mol Biosci. 2021;8:728777. https:\/\/doi.org\/10.3389\/fmolb.2021.728777.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"4064_CR47","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal Transduct Target Ther. 2023;8(1):420. https:\/\/doi.org\/10.1038\/s41392-023-01647-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"4064_CR48","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","volume":"124","author":"T Shorstova","year":"2021","unstructured":"Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer. 2021;124(9):1478\u201390. https:\/\/doi.org\/10.1038\/s41416-021-01321-0.","journal-title":"Br J Cancer"},{"issue":"14","key":"4064_CR49","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.3390\/ijms22147340","volume":"22","author":"AI Khamidullina","year":"2021","unstructured":"Khamidullina AI, Varlamova EA, Hammoud NA, Yastrebova MA, Bruter AV. Gene transcription as a therapeutic target in leukemia. Int J Mol Sci. 2021;22(14):7340\u20137340. https:\/\/doi.org\/10.3390\/ijms22147340.","journal-title":"Int J Mol Sci"},{"key":"4064_CR50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41580-019-0151-1","volume":"20","author":"A Jambhekar","year":"2019","unstructured":"Jambhekar A, Dhall A, Shi Y. Roles and regulation of histone methylation in animal development. Nat Rev Mol Cell Biol. 2019;20:625\u201341. https:\/\/doi.org\/10.1038\/s41580-019-0151-1.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"4064_CR51","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/tcr.201800082","volume":"18","author":"MD Fulton","year":"2018","unstructured":"Fulton MD, Brown T, Zheng YG. Mechanisms and inhibitors of histone arginine methylation. Chem Record (New York, NY). 2018;18(12):1792\u2013807. https:\/\/doi.org\/10.1002\/tcr.201800082.","journal-title":"Chem Record (New York, NY)"},{"key":"4064_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13148-016-0223-4","volume":"8","author":"L Morera","year":"2016","unstructured":"Morera L, L\u00fcbbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenet. 2016;8:57. https:\/\/doi.org\/10.1186\/s13148-016-0223-4.","journal-title":"Clin Epigenet"},{"issue":"6","key":"4064_CR53","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/odi.12569","volume":"23","author":"MK Kang","year":"2017","unstructured":"Kang MK, Mehrazarin S, Park NH, Wang CY. Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation. Oral Dis. 2017;23(6):709\u201320. https:\/\/doi.org\/10.1111\/odi.12569.","journal-title":"Oral Dis"},{"issue":"10","key":"4064_CR54","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.3390\/ijms23105801","volume":"23","author":"IV Bure","year":"2022","unstructured":"Bure IV, Nemtsova MV, Kuznetsova EB. Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis. Int J Mol Sci. 2022;23(10):5801. https:\/\/doi.org\/10.3390\/ijms23105801.","journal-title":"Int J Mol Sci"},{"key":"4064_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.848221","author":"Y Jin","year":"2022","unstructured":"Jin Y, Liu T, Luo H, Liu Y, Liu D. Targeting epigenetic regulatory enzymes for cancer therapeutics: novel small-molecule epidrug development. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.848221.","journal-title":"Front Oncol"},{"issue":"4","key":"4064_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jncc.2022.09.002","volume":"2","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Center. 2022;2(4):277\u201390. https:\/\/doi.org\/10.1016\/j.jncc.2022.09.002.","journal-title":"J Natl Cancer Center"},{"issue":"2","key":"4064_CR57","doi-asserted-by":"publisher","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","volume":"13","author":"R Straining","year":"2022","unstructured":"Straining R, Eighmy W. Tazemetostat: EZH2 inhibitor. J Adv Pract Oncol. 2022;13(2):158\u201363. https:\/\/doi.org\/10.6004\/jadpro.2022.13.2.7.","journal-title":"J Adv Pract Oncol"},{"issue":"17","key":"4064_CR58","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2217\/fon-2020-1244","volume":"17","author":"E Julia","year":"2021","unstructured":"Julia E, Salles G. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma. Future Oncol (London, England). 2021;17(17):2127\u201340. https:\/\/doi.org\/10.2217\/fon-2020-1244.","journal-title":"Future Oncol (London, England)"},{"key":"4064_CR59","doi-asserted-by":"publisher","first-page":"115982","DOI":"10.1016\/j.ejmech.2023.115982","volume":"264","author":"D Li","year":"2023","unstructured":"Li D, Peng X, Hu Z, Li S, Chen J, Pan W. Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: current progress and novel strategies. Eur J Med Chem. 2023;264:115982. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115982.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"4064_CR60","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11523-020-00717-x","volume":"15","author":"M Ratti","year":"2020","unstructured":"Ratti M, Lampis A, Ghidini M, Salati M, Mirchev MB, Valeri N, et al. Micrornas (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 2020;15(3):261\u201378. https:\/\/doi.org\/10.1007\/s11523-020-00717-x.","journal-title":"Target Oncol"},{"key":"4064_CR61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96\u2013118. https:\/\/doi.org\/10.1038\/s41580-020-00315-9.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4064_CR62","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","volume":"23","author":"HA Malone","year":"2024","unstructured":"Malone HA, Roberts CWM. Chromatin remodellers as therapeutic targets. Nat Rev Drug Discov. 2024;23:661\u201381. https:\/\/doi.org\/10.1038\/s41573-024-00978-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"4064_CR63","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1080\/15592294.2019.1640546","volume":"14","author":"CL Miranda Furtado","year":"2019","unstructured":"Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos RD, Furtado GP, Moraes MO, Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14(12):1164\u201376. https:\/\/doi.org\/10.1080\/15592294.2019.1640546.","journal-title":"Epigenetics"},{"issue":"1","key":"4064_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01098-2","volume":"13","author":"T Yang","year":"2021","unstructured":"Yang T, Yang Y, Wang Y. Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy. Clin Epigenetics. 2021;13(1):113. https:\/\/doi.org\/10.1186\/s13148-021-01098-2.","journal-title":"Clin Epigenetics"},{"key":"4064_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32509-4","author":"ABA Laranjeira","year":"2023","unstructured":"Laranjeira ABA, Hollingshead MG, Nguyen D, Kinders RJ, Doroshow JH, Yang SX. DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-32509-4.","journal-title":"Sci Rep"},{"issue":"23","key":"4064_CR66","doi-asserted-by":"publisher","first-page":"5926","DOI":"10.3390\/cancers14235926","volume":"14","author":"A Elrakaybi","year":"2022","unstructured":"Elrakaybi A, Ruess DA, L\u00fcbbert M, Quante M, Becker H. Epigenetics in pancreatic ductal adenocarcinoma: impact on biology and utilization in diagnostics and treatment. Cancers. 2022;14(23):5926\u20135926. https:\/\/doi.org\/10.3390\/cancers14235926.","journal-title":"Cancers"},{"key":"4064_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.818891","author":"HA Ali","year":"2022","unstructured":"Ali HA, Li Y, Bilal AHM, Qin T, Yuan Z, Zhao W. A comprehensive review of BET protein biochemistry, physiology, and pathological roles. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.818891.","journal-title":"Front Pharmacol"},{"issue":"10","key":"4064_CR68","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1535-7163.mct-21-0029","volume":"20","author":"L Zhang","year":"2021","unstructured":"Zhang L, Cai T, Lin X, Huang X, Bui MH, Plotnik JP, et al. Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia. Mol Cancer Ther. 2021;20(10):1809\u201319. https:\/\/doi.org\/10.1158\/1535-7163.mct-21-0029.","journal-title":"Mol Cancer Ther"},{"key":"4064_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1193344","author":"MD Basta","year":"2023","unstructured":"Basta MD, Petruk S, Mazo A, Walker JL. Fibrosis\u2014the tale of H3K27 histone methyltransferases and demethylases. Front Cell Dev Biol. 2023. https:\/\/doi.org\/10.3389\/fcell.2023.1193344.","journal-title":"Front Cell Dev Biol"},{"key":"4064_CR70","doi-asserted-by":"publisher","first-page":"175590","DOI":"10.1016\/j.ejphar.2023.175590","volume":"944","author":"LL Marzochi","year":"2023","unstructured":"Marzochi LL, Cuzziol CI, Henrique C, Amorim J, Urbanin M, Pavarino \u00c9C, et al. Use of histone methyltransferase inhibitors in cancer treatment: a systematic review. Eur J Pharmacol. 2023;944:175590\u2013175590. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175590.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"4064_CR71","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/cancers13071746","volume":"13","author":"M Maher","year":"2021","unstructured":"Maher M, Diesch J, Le Pann\u00e9rer M-M, Buschbeck M. Epigenetics in a spectrum of myeloid diseases and its exploitation for therapy. Cancers. 2021;13(7):1746\u20131746. https:\/\/doi.org\/10.3390\/cancers13071746.","journal-title":"Cancers"},{"key":"4064_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01341-7","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01341-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4064_CR73","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","volume":"55","author":"T Kim","year":"2023","unstructured":"Kim T, Croce CM. Microrna: trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med. 2023;55(7):1314\u201321. https:\/\/doi.org\/10.1038\/s12276-023-01050-9.","journal-title":"Exp Mol Med"},{"issue":"1","key":"4064_CR74","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2023","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2023;21(1):7\u201324. https:\/\/doi.org\/10.1038\/s41575-023-00840-w.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4064_CR75","doi-asserted-by":"publisher","first-page":"188676","DOI":"10.1016\/j.bbcan.2022.188676","volume":"1877","author":"X-S Xiang","year":"2022","unstructured":"Xiang X-S, Li P-C, Wang W-Q, Liu L. Histone deacetylases: a novel class of therapeutic targets for pancreatic cancer. Biochim Biophys Acta (BBA) Rev Cancer. 2022;1877(1):188676\u2013188676. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188676.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"key":"4064_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.621093","author":"Y Sun","year":"2021","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2020.621093.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4064_CR77","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/cancers13051092","volume":"13","author":"C Hervieu","year":"2021","unstructured":"Hervieu C, Christou N, Battu S, Mathonnet M. The role of cancer stem cells in colorectal cancer: from the basics to novel clinical trials. Cancers. 2021;13(5):1092\u20131092. https:\/\/doi.org\/10.3390\/cancers13051092.","journal-title":"Cancers"},{"issue":"4","key":"4064_CR78","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M, Luo H-Y, Fang W-J, Wang Y-N, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30(4):1035\u201343. https:\/\/doi.org\/10.1038\/s41591-024-02813-1.","journal-title":"Nat Med"},{"key":"4064_CR79","doi-asserted-by":"publisher","first-page":"102223","DOI":"10.1016\/j.ctrv.2021.102223","volume":"98","author":"E Crimini","year":"2021","unstructured":"Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G. Precision medicine in breast cancer: from clinical trials to clinical practice. Cancer Treat Rev. 2021;98:102223\u2013102223. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102223.","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"4064_CR80","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.34974","volume":"129","author":"R Parveen","year":"2023","unstructured":"Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372\u201380. https:\/\/doi.org\/10.1002\/cncr.34974.","journal-title":"Cancer"},{"issue":"7","key":"4064_CR81","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/1078-0432.ccr-21-3729","volume":"28","author":"MR Baer","year":"2022","unstructured":"Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, et al. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2022;28(7):1313\u201322. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-3729.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4064_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00277-023-05552-4","volume":"103","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, et al. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes\/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2023;103(1):105\u201316. https:\/\/doi.org\/10.1007\/s00277-023-05552-4.","journal-title":"Ann Hematol"},{"issue":"1","key":"4064_CR83","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drudis.2021.08.007","volume":"27","author":"W Jin","year":"2022","unstructured":"Jin W, Tan H, Wu J, He G, Liu B. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: current situation and future directions. Drug Discov Today. 2022;27(1):246\u201356. https:\/\/doi.org\/10.1016\/j.drudis.2021.08.007.","journal-title":"Drug Discov Today"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04064-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04064-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:11:07Z","timestamp":1774415467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04064-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":83,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4064"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04064-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}